Wolfe Research Upgrades Johnson & Johnson(JNJ.US) to Buy Rating, Raises Target Price to $190
Express News | Johnson & Johnson - Nipocalimab Shows 77% Igg Reduction in Phase 2 Study
Express News | Nipocalimab Demonstrates Significant Clinical Improvement in Disease Activity and Igg Reduction in Phase 2 Sjögren's Disease Study
Express News | Johnson & Johnson Medtech Announces Strategic Agreement With Responsive Arthroscopy to Expand Sports Soft Tissue Solutions
Sector Update: Health Care Stocks Edge Lower Wednesday Afternoon
Johnson & Johnson Sues US Government Over Rebate Model in Drug Discount Program